Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 3/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 5/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.30 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22024008 | 1.00 | CCR2 (0.36) | CCR2CCR1CCR5CXCR4ALDH1A1 | |
| SCHEMBL21191549 | 0.86 | PDE4A (0.34) | CCR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21884191 | 0.84 | CCR2 (0.34) | CCR2CCR1CCR5CXCR4ALDH1A1 | |
| SCHEMBL22024174 | 0.84 | CCR2 (0.33) | CCR2CCR1CCR5CXCR4ALDH1A1 | |
| SCHEMBL22023926 | 0.80 | PDE4A (0.35) | ALDH1A1L3MBTL1PDE4APDE4BPDE4C | |
| SCHEMBL22023911 | 0.79 | SLC2A1 (0.35) | ALDH1A1PDE4A | |
| SCHEMBL22023873 | 0.73 | PDE4A (0.33) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23745425 | 0.73 | CCR2 (0.35) | CCR2 | |
| SCHEMBL22023908 | 0.73 | GNAO1 (0.43) | CCR2CCR1CCR5CXCR4 | |
| SCHEMBL18673262 | 0.72 | GNAO1 (0.46) | CCR2CCR1CCR5CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11058678-B2 | Substituted heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11058678-B2 | Substituted heterocycles as antiviral agents | HCCS, HDGF, HAVCR2 | CCR2 1219/4885CCR1 1419/4885CCR5 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.